Postoperative radiotherapy of carcinoma in bilharzial bladder using a three-fractions per day regimen.
Patients with T3 bladder cancer who survived surgery and proved to have P3a, P3b or P4a tumors were randomized to either no further treatment (61 patients) or postoperative total pelvic irradiation (55 patients). A three-fraction per day regime was adopted with a dose per fraction of 125 cGy and an interval of 3 h between fractions. The total dose amounted to 3750 cGy divided into 30 fractions over 12 days. Patients of the postoperative radiotherapy group were re-randomized to radiotherapy alone or radiotherapy plus misonidazole (MISO) in a daily dose of 1 g/m2 given orally 2 h before the first daily fraction. The 2-year disease-free survival rate in the cystectomy alone group was 33 +/- 6% compared to 65 +/- 6% in the postoperative radiotherapy group. The therapeutic benefit applied to the two cell types, all histological grades and stages and to patients with or without nodal metastases. The benefit of postoperative irradiation was also verified by the Cox's multivariant analysis which adjusts for the relative representation of the important prognostic factors particularly pathological stage and nodal involvement. MISO did not seem to add to the therapeutic gain. No late complications were encountered in the wall of the rectum, small bowel or uretero-intestinal anastomotic sites. This is suggested to be due to the small dose per fraction used. However, early small bowel reactions were dose-limiting.
D000328:Adult; D002986:Clinical Trials as Topic; D003037:Cobalt Radioisotopes / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003556:Cystitis / Q000401:mortality / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008920:Misonidazole / Q000009:adverse effects / Q000627:therapeutic use; D011182:Postoperative Care / Q000379:methods*; D011446:Prospective Studies; D011867:Radioisotope Teletherapy; D011879:Radiotherapy Dosage; D011897:Random Allocation; D012552:Schistosomiasis / Q000401:mortality / Q000532:radiotherapy*; D001749:Urinary Bladder Neoplasms / Q000401:mortality / Q000532:radiotherapy*
D003037:Cobalt Radioisotopes; D008920:Misonidazole